Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

PubWeight™: 4.05‹?› | Rank: Top 1%

🔗 View Article (PMID 21300762)

Published in Clin Cancer Res on February 07, 2011

Authors

Patricia M LoRusso1, Charles M Rudin, Josina C Reddy, Raoul Tibes, Glen J Weiss, Mitesh J Borad, Christine L Hann, Julie R Brahmer, Ilsung Chang, Walter C Darbonne, Richard A Graham, Kenn L Zerivitz, Jennifer A Low, Daniel D Von Hoff

Author Affiliations

1: Karmanos Cancer Institute, Detroit, Michigan; Johns Hopkins University, Baltimore, Maryland, USA.

Associated clinical trials:

Matching Patients With Hematologic Malignancy to Adequate Clinical Trials | NCT02758080

Articles citing this

(truncated to the top 100)

Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med (2012) 6.90

The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer (2011) 2.60

Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med (2013) 2.55

Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov (2014) 2.55

Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. Cancer Cell (2014) 2.30

Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res (2011) 2.12

Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89

Advanced basal cell carcinoma. Wien Med Wochenschr (2013) 1.71

HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature (2016) 1.53

Insight into early-phase trials for lung cancer in the United States. Chin J Cancer (2015) 1.46

Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol (2012) 1.40

Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med (2014) 1.38

Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS One (2011) 1.37

Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol (2012) 1.36

Molecular pathways: the hedgehog signaling pathway in cancer. Clin Cancer Res (2012) 1.26

Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res (2013) 1.25

Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol (2012) 1.24

Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int (2012) 1.23

Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res (2013) 1.20

Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res (2014) 1.20

The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer. Oncotarget (2011) 1.17

Vismodegib. Nat Rev Drug Discov (2012) 1.16

Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res (2011) 1.15

GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett (2012) 1.14

Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist (2013) 1.09

Vismodegib. Clin Cancer Res (2012) 1.07

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood (2012) 1.07

Signal Transduction Pathways of EMT Induced by TGF-β, SHH, and WNT and Their Crosstalks. J Clin Med (2016) 1.07

Basal cell carcinoma - molecular biology and potential new therapies. J Clin Invest (2012) 1.06

Vismodegib (erivedge) for advanced Basal cell carcinoma. P T (2012) 1.02

Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas. J Exp Clin Cancer Res (2014) 1.01

The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Res (2013) 1.01

Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol (2015) 1.00

Targeting hedgehog signaling in cancer: research and clinical developments. Onco Targets Ther (2013) 0.99

Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma (2012) 0.99

Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Cancer Res (2015) 0.99

Regulation of DNA damage following termination of Hedgehog (HH) survival signaling at the level of the GLI genes in human colon cancer. Oncotarget (2012) 0.97

The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother (2013) 0.97

Desmoplasia in pancreatic cancer. Can we fight it? Gastroenterol Res Pract (2012) 0.96

Hedgehog signaling in prostate cancer and its therapeutic implication. Int J Mol Sci (2013) 0.96

The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia (2015) 0.96

Down-regulation of Gli transcription factor leads to the inhibition of migration and invasion of ovarian cancer cells via integrin β4-mediated FAK signaling. PLoS One (2014) 0.94

Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding. Oncotarget (2014) 0.94

The utility of hedgehog signaling pathway inhibition for cancer. Oncologist (2012) 0.94

The rationale for targeted therapies in medulloblastoma. Neuro Oncol (2013) 0.92

Gli as a novel therapeutic target in malignant pleural mesothelioma. PLoS One (2013) 0.91

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. J Hematol Oncol (2014) 0.91

An old friend with new skills: Imiquimod as novel inhibitor of Hedgehog signaling in basal cell carcinoma. Oncoscience (2014) 0.91

Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthal Plast Reconstr Surg (2013) 0.90

GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann Oncol (2013) 0.90

Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastasis (2015) 0.90

Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened. Oncotarget (2015) 0.89

Targeting bet bromodomain proteins in solid tumors. Oncotarget (2016) 0.89

Targeting Gli transcription activation by small molecule suppresses tumor growth. Oncogene (2013) 0.88

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol (2015) 0.87

Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy. Expert Rev Mol Med (2015) 0.87

Ectopic overexpression of Sonic Hedgehog (Shh) induces stromal expansion and metaplasia in the adult murine pancreas. Neoplasia (2011) 0.87

Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res (2013) 0.87

Aberrant GLI1 Activation in DNA Damage Response, Carcinogenesis and Chemoresistance. Cancers (Basel) (2015) 0.86

Advanced treatment for basal cell carcinomas. Cold Spring Harb Perspect Med (2014) 0.86

Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation. Oncogene (2013) 0.86

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol (2012) 0.86

Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers (Basel) (2012) 0.85

Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma. Cancer Manag Res (2013) 0.85

Molecular targeted approaches for treatment of pancreatic cancer. Curr Pharm Des (2011) 0.85

Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors. Biologics (2015) 0.85

Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas. Indian J Pharmacol (2014) 0.84

Targeting the Hedgehog pathway in cancer: can the spines be smoothened? Clin Cancer Res (2011) 0.84

New insights into pancreatic cancer stem cells. World J Stem Cells (2015) 0.84

Targeted treatment for sonic hedgehog-dependent medulloblastoma. Neuro Oncol (2014) 0.83

Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma. United European Gastroenterol J (2013) 0.83

Hedgehog signaling pathway and ovarian cancer. Chin J Cancer Res (2013) 0.83

Matching mice to malignancy: molecular subgroups and models of medulloblastoma. Childs Nerv Syst (2012) 0.83

Sonic Hedgehog in pancreatic cancer: from bench to bedside, then back to the bench. Surgery (2012) 0.83

Sonic hedgehog signaling in Basal cell nevus syndrome. Cancer Res (2014) 0.83

Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma. J Adv Pract Oncol (2015) 0.83

Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma. Oncotarget (2013) 0.83

Progress and renewal in gustation: new insights into taste bud development. Development (2015) 0.83

Novel small molecules targeting ciliary transport of Smoothened and oncogenic Hedgehog pathway activation. Sci Rep (2016) 0.82

Novel therapies for the treatment of advanced prostate cancer. Curr Treat Options Oncol (2013) 0.82

Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer. Oncotarget (2015) 0.82

Hedgehog signaling pathway in ovarian cancer. Int J Mol Sci (2013) 0.82

The roles of FOXM1 in pancreatic stem cells and carcinogenesis. Mol Cancer (2013) 0.82

Semi-Mechanism-Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor Vismodegib. CPT Pharmacometrics Syst Pharmacol (2015) 0.82

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer (2017) 0.81

BRD4 induces cell migration and invasion in HCC cells through MMP-2 and MMP-9 activation mediated by the Sonic hedgehog signaling pathway. Oncol Lett (2015) 0.81

Targeting stem cell behavior in desmoid tumors (aggressive fibromatosis) by inhibiting hedgehog signaling. Neoplasia (2013) 0.81

Genetic and molecular alterations across medulloblastoma subgroups. J Mol Med (Berl) (2015) 0.81

The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo. Oncotarget (2016) 0.80

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. J Hematol Oncol (2015) 0.80

Targeting cancer stem cells in solid tumors by vitamin D. J Steroid Biochem Mol Biol (2014) 0.80

In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. Oncotarget (2016) 0.80

MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor. FASEB J (2015) 0.80

A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib. Cancer Chemother Pharmacol (2016) 0.80

Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas. World J Clin Cases (2014) 0.79

Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression. J Biol Chem (2014) 0.79

Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling. Bioorg Med Chem (2012) 0.79

Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome. Dermatol Reports (2011) 0.79

Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndrome. Ann Maxillofac Surg (2015) 0.79

Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment. Oncotarget (2016) 0.79

Articles cited by this

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40

Hedgehog signaling in animal development: paradigms and principles. Genes Dev (2001) 14.75

Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev (2002) 8.56

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55

A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 8.16

Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science (1996) 8.06

Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell (1996) 7.86

Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature (1998) 7.43

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40

Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov (2006) 5.30

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature (2009) 4.99

Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer (2008) 4.34

Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci (2009) 3.74

Sporadic medulloblastomas contain PTCH mutations. Cancer Res (1997) 3.22

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell (2008) 3.01

Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med (2007) 2.62

Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology (2004) 2.47

Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell (2008) 2.42

GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett (2009) 2.17

Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res (2011) 2.12

A CONGENITAL CYCLOPIAN-TYPE MALFORMATION IN LAMBS INDUCED BY MATERNAL INGESTION OF A RANGE PLANT, VERATRUM CALIFORNICUM. Am J Vet Res (1963) 1.53

The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. Br J Cancer (1997) 1.49

Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 1.20

Hedgehog signaling pathway as a target for therapeutic intervention in basal cell carcinoma. Drug News Perspect (2003) 1.02

Articles by these authors

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 9.35

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23

Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med (2012) 6.90

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol (2010) 6.34

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60

American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol (2004) 4.48

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 4.14

DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature (2011) 3.90

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol (2008) 3.83

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68

Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther (2007) 3.61

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53

A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 3.38

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol (2011) 3.33

Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A (2009) 3.13

Functional proteomic profiling of AML predicts response and survival. Blood (2008) 2.90

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88

Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res (2009) 2.77

Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71

Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell (2013) 2.62

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.59

Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res (2002) 2.55

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol (2005) 2.53

The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther (2002) 2.39

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol (2006) 2.32

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood (2006) 2.31

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res (2003) 2.27

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res (2007) 2.25

Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res (2011) 2.12

ALK-targeted therapy for lung cancer: ready for prime time. Oncology (Williston Park) (2011) 2.11

Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09

MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther (2008) 2.05

Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04

Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res (2008) 1.99

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol (2010) 1.93

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol (2008) 1.91

miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol (2011) 1.78

Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys (2011) 1.78

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med (2015) 1.75

Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer (2011) 1.74

RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. Gynecol Oncol (2010) 1.73

The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol (2013) 1.70

A combinatorial strategy for treating KRAS-mutant lung cancer. Nature (2016) 1.69

Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood (2008) 1.67

PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther (2005) 1.67

Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr (2006) 1.66

Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos (2003) 1.66

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther (2004) 1.65

Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer (2011) 1.64

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res (2010) 1.63

Isolated supraclavicular lymph node metastasis in pancreatic adenocarcinoma: a report of three cases and review of the literature. JOP (2010) 1.60

Establishment and characterization of a primary human chordoma xenograft model. J Neurosurg (2012) 1.60

MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer (2011) 1.55

Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther (2004) 1.54

Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. J Thorac Oncol (2014) 1.53

Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst (2007) 1.52

IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology (2015) 1.52

Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol (2007) 1.50

Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res (2011) 1.49

RuleMonkey: software for stochastic simulation of rule-based models. BMC Bioinformatics (2010) 1.49

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med (2009) 1.48

Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma (2014) 1.46

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol (2014) 1.45

Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget (2013) 1.44

Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol (2006) 1.44

Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther (2006) 1.41

Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res (2013) 1.41